SUPRAME: A Phase 3 trial evaluating anzutresgene autoleucel (anzu-cel, IMA203) PRAME-directed T-cell receptor T-cell therapy vs investigator’s choice in previously treated advanced cutaneous melanoma

EJC Skin Cancer · Published 2026-01-01 · DOI 10.1016/j.ejcskn.2026.100916

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ejcskn.2026.100916

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year
2026

Related articles